|
Name: Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine
Type: Benzodiazepine
AKA: ['8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1', '2', '4]triazolo[4', '3-a][1', '4]benzodiazepine']
![Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine image](https://grammasearch.com/dev/v2/img/benzo.png)
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
III. Chemical Profile (IUPAC name)
![Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine) image](/dev/v2/pages/pubchem_images/11704817.png)
|
|
IV. History
Flubromazolam, a potent benzodiazepine, was first synthesized in the early 2010s as part of research into new anxiolytics. It was developed to provide enhanced sedative and anxiolytic effects compared to other benzodiazepines. The substance's appearance in the recreational drug market was part of a trend towards new psychoactive substances with strong effects. Flubromazolam's potent sedative properties and associated risks have led to its regulation in many countries due to concerns about misuse and health risks.
|
|
V. Legal Information
Flubromazolam is a potent benzodiazepine with strong sedative effects. It is controlled in many countries due to its potential for misuse and addiction. In the United States, it is often classified as a Schedule I substance, reflecting its high abuse potential. Internationally, regulations focus on preventing its illegal distribution and use. [Source: UNODC].
US Federal Schedule - I
Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Some examples of Schedule I drugs are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
Flubromazolam is a benzodiazepine with sedative and anxiolytic effects. It causes sedation, reduced heart rate, and impaired motor function. Short-term use is effective for anxiety management, but long-term use can lead to dependence, cognitive impairment, and significant health issues. Overdose risks include severe sedation, respiratory depression, and potential death. Safe use involves following prescribed dosages. Recent research explores its efficacy in managing anxiety and highlights associated risks.  |
|
VII. Psychological Effects
N/A
 |
|
VIII. Culture
Flubromazolam is a potent benzodiazepine with anxiolytic and sedative effects. Its cultural significance is associated with its use in recreational settings and its potential for abuse. Media coverage often focuses on the risks and effects of benzodiazepines, including overdose and addiction. Flubromazolam is used recreationally rather than medicinally and contributes to discussions about drug regulation and harm reduction.
 |